These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 38217824)

  • 21. Novel Approaches for Systemic Mastocytosis.
    Fletcher L; Borate U
    Curr Opin Hematol; 2019 Mar; 26(2):112-118. PubMed ID: 30694839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding.
    Afrin LB; Dempsey TT; Rosenthal LS; Dorff SR
    J Obstet Gynaecol; 2019 Jul; 39(5):664-669. PubMed ID: 30964355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mastocytosis and related entities: a practical roadmap.
    Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
    Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
    Baird JH; Gotlib J
    Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mast cell activation syndrome: Myths and realities.
    Zhang S; Bernstein JA
    Allergy Asthma Proc; 2021 May; 42(3):198-204. PubMed ID: 33980332
    [No Abstract]   [Full Text] [Related]  

  • 27. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
    Valent P; Hartmann K; Bonadonna P; Niedoszytko M; Triggiani M; Arock M; Brockow K
    Int Arch Allergy Immunol; 2022; 183(7):693-705. PubMed ID: 35605594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
    Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME;
    J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2023 Jul; 98(7):1097-1116. PubMed ID: 37309222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mast cell activation syndromes presenting as anaphylaxis.
    Akin C
    Immunol Allergy Clin North Am; 2015 May; 35(2):277-85. PubMed ID: 25841551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mast cell activation syndromes: definition and classification.
    Valent P
    Allergy; 2013 Apr; 68(4):417-24. PubMed ID: 23409940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
    Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
    Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.
    Gülen T
    Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.
    Jensen BM; Akin C; Gilfillan AM
    Br J Pharmacol; 2008 Aug; 154(8):1572-82. PubMed ID: 18500355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antineoplastic efficacy profiles of avapritinib and nintedanib in
    Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
    Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.
    Bai Y; Bandara G; Ching Chan E; Maric I; Simakova O; Bandara SN; Lu WP; Wise SC; Flynn DL; Metcalfe DD; Gilfillan AM; Wilson TM
    Leukemia; 2013 Feb; 27(2):278-85. PubMed ID: 22907049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Pardanani A; Reichard K; Tefferi A
    Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.